Ankylosing spondylitis in west Africans—evidence for a non-HLA-B*27 protective effect

Dr Brown and his colleagues are to be congratulated for performing a logistically formidable, but necessary, epidemiological study testing the currently in vogue hypothesis that the B*2703 subtype of HLA-B27 is not related to ankylosing spondylitis (AS). They conclude that the B*2705 subtype, as well as B*2703, possesses a lower risk for developing AS in a group of B27 positive west Africans, the Fula from Gambia, when compared to white people with positive HLA-B27 white subject confirming the potential protective role of an environmental factor(s). This conclusion is based on an assumed risk of developing AS in B27 positive persons of 11.1% for men and 1.5% for women. No cases of AS were seen among 900 adult Fula men and 215 first degree relatives of 48 B27 positive Fula twin pairs. We would argue that the data warrant a more conservative conclusion implied in the discussion, namely, the risk of AS among B27 positive Fula subjects would need to be at least 2.7% in men and 1% in women to assign significance to the finding of no AS in this population.

The risk of developing AS in HLA-B27 positive subjects clearly varies among different ethnic groups, but it is now generally accepted that among white populations, the prevalence of AS is nearer 1–2% rather than 10–15%. The Norwegian survey of 14,539 subjects quoted by the authors is in fact based on a highly selected sample of only 375 people responding positively to a questionaire for low back pain or stiffness who actually turned up for examination and had x rays of sacroiliac joints. You arrive at an entirely different conclusion if you apply the AS prevalence figures of 1.4% for B27 subjects from the Busselton population study or 1.3% of Dutch B27 positive subjects. The second study examined 2956 subjects older than 44 years who all had sacroiliac x rays and only three B27 positive subjects had AS according to the New York criteria leading to a prevalence of 0.1%. Recalculating the data of Brown et al according to these more generally accepted prevalence rates leads to the following conclusions. The probability of observing no cases of AS in 900 adult Fula men would be 46.9% (that is, p=0.47). The number of B*2703 persons expected to develop AS would be zero, as in fact observed in this study. Indeed, no case has yet been reported from the Gambian AS population. Even assuming a risk of 2.7% for AS in the total study population (n=1115), we would expect 30 cases of AS, a number which is found. Given that a high proportion of estimates are made at the time of the acute episode a correct diagnosis may depend on a practitioner’s knowledge of the fact that the SUA may be within the ‘normal range’ at this time. Most, if not all rheumatologists, are more likely to be involved with other diseases.

Authors’ reply

We would like to thank Dr Maksymowych for his interest in our study. We agree with his conclusion that our study shows that B27 is not associated with ankylosing spondylitis (AS) in the Gambia. We conclude that the risk of AS in B27 positive men is greater than 2.7% and women is greater than 1% (which we believe to be the case). We feel that most of his criticisms can be satisfactorily answered.

The risk of developing AS in B27 positive subjects is uncertain. The studies mentioned by Dr Maksymowych are among the lowest estimates that have been reported for white populations. Other studies have reported that as many as 20% of B27 positive subjects may develop the disease. The survey by Gran et al is by far the largest reported: 21,329 subjects were invited to participate in a study of cardiovascular disease, of whom 16,621 attended screening sessions. Of these, 14,539 (87%) completed questionnaires including questions about back problems; 2907 reported a history of pain or stiffness in the back—the remainder were asymptomatic. From this group a random sample of 806 were invited to attend for clinical screening, of which 449 did; 375 of these had sacroiliac radiographs. Comparisons at each step demonstrated that selection bias was minimal. We believe therefore that not only is this study significantly larger than either of the studies mentioned by Dr Maksymowych, but is also reliable. It is also the only study of sufficient size to determine the risk for AS among men and women with B27 separately, which was a requirement for our analysis.

The risk for AS among B27 positive men is significantly greater than B27 positive women. In our study 1008 participants were male and 107 female. Therefore it was important to use sex-specific risk estimates, which Dr Maksymowych has not used in his calculations. Also, the study examined 215 relatives of 48 B27 positive subjects in addition to the 900 adult Fula men used in Dr Maksymowych’s calculations. Analysing the total study population (n=1115), we showed that the risk associated with B27 in the Gambia (p<0.05), assuming that the risk of AS was 1.85% in B27 positive subjects, and that men were 2.7 times more likely to develop disease than women (both of these assumptions are conservative). Using a higher male/female ratio would allow us to exclude even lower degrees of association of B27 with AS.

Our study confirmed the previous finding that AS is extremely rare in west Africa—indeed no case has yet been reported from the Gambia. This is despite the prevalence of B27 being as high as 7.8% in some ethnic groups. The fact that 68% of B27 positive subjects in this area carry B*2705 indicates that it is not a difference in B27 subtypes that explains the rarity of the disease. Furthermore, two separate groups have now reported cases of AS in B*2703 subjects.

It remains possible that B*2703 has a lower risk for AS than other disease associated subtypes. However AS is not associated with either B*2703 or B*2705 in the Gambia. Future comparisons of the strength of association of B27 subtypes with AS need to consider other environmental and genetic differences between the different populations studied.

MATTERS ARISING

LETTERS

Serum uric acid in acute gout

The relation between gout and uric acid is such that in general clinical practice there is a tendency (diminishing) to misdiagnose gout in the presence of hyperuricaemia. Conversely the diagnosis of gout may be rejected when a normal serum uric acid (SUAA) value is found. Given that a high proportion of estimation are made at the time of the acute episode a correct diagnosis may depend on a practitioner’s knowledge of the fact that the SUAA may be within the ‘normal range’ at this time. Most, if not all rheumatologists, are...
Matters arising, Letters


Giant cell arteritis of the leg in a patient with hepatitis C virus infection

The potential association of chronic hepatitis C virus (HCV) infection with a variety of dermatological features has been reported. In particular, it has been observed that different types of cutaneous vasculitis may develop during the course of HCV infection, such as mixed cryoglobulinaemia related leucocytoclastic vasculitis and polyarteritis nodosa.

We report a case of giant cell arteritis (GCA) involving the medium sized dermal arteries of the right leg, which appeared after a long history of HCV infection. A 44 year old man with an eight year history of chronic hepatitis was admitted to the Rheumatology/Clinical Immunology Units of the University of Pisa in July 1995 because of erythematous cutaneous nodules on the legs. Chronic hepatitis had been suspected since 1987 because of raised, fluctuating values of hepatic enzymes. In 1993 the diagnosis was confirmed by liver biopsy. In June 1995 the presence of anti-HCV antibodies was demonstrated by an ELISA test. From the time of the histopathological assessment of chronic hepatitis to that of the appearance of the cutaneous nodules the patient was not receiving any medical treatment.

At the time of his stay in hospital the patient underwent a complete physical examination, which showed no abnormalities except for the cutaneous lesions. These were tender, red, and painful nodules situated on the medial side of the right leg, which appeared to be confluent in some areas.

Routine laboratory investigation showed only a moderate increase of the acute phase reactants (erythrocyte sedimentation rate 20 mm 1st h, C reactive protein 2.9 mg/dl, fibrinogen 600 mg/dl).

Antineutrophil cytoplasmatic antibodies (ANCA), antinuclear antibodies, immune complexes, and cryoglobulins were absent. Hepatitis B virus markers (antibodies to hepatitis B, anti-HBc, and anti-HBe) and the serum, nor were the antibodies anti-HIV1 and -HIV2.

On the contrary, anti-HCV antibodies were found using a third generation ELISA test (Abbott HCV EIA 3.0, Abbott Diagnostics, Wiesbaden-Dielenkheim, Germany). A qualitative ‘dot’ assay (Abbott HCV MA-TRIX, Abbott Diagnostics, Wiesbaden-Dielenkheim, Germany) showed that these antibodies were directed to the HC-34 core protein (anti-HBc, anti-HBe, and the HBs and HBc antigens) were not detected in the serum. From the time of the histopathological assessment of chronic hepatitis to that of the appearance of the cutaneous nodules the patient was not receiving any medical treatment.

Antineutrophil cytoplasmatic antibodies (ANCA), antinuclear antibodies, immune complexes, and cryoglobulins were absent. Hepatitis B virus markers (antibodies to hepatitis B, anti-HBc, and anti-HBe) and the HBs and HBc antigens) were not detected in the serum, nor were the antibodies anti-HIV1 and -HIV2.

On the contrary, anti-HCV antibodies were found using a third generation ELISA test (Abbott HCV EIA 3.0, Abbott Diagnostics, Wiesbaden-Dielenkheim, Germany). A qualitative ‘dot’ assay (Abbott HCV MA-TRIX, Abbott Diagnostics, Wiesbaden-Dielenkheim, Germany) showed that these antibodies were directed to the HC-34 core protein (anti-HBc, anti-HBe, and the HBs and HBc antigens) were not detected in the serum.

From the time of the histopathological assessment of chronic hepatitis to that of the appearance of the cutaneous nodules the patient was not receiving any medical treatment.

The presence of viral RNA (indicative of active HCV replication) in the serum was demonstrated by a polymerase chain reaction.

Figure 1 Urate values in acute and interval gout.

![Urate values in acute and interval gout](image-url)

We have conducted a prospective study to determine the frequency of normal SUA values in acute gout and also to compare acute and intercritical values.

Over a period of three years we observed 38 consecutive patients during 42 episodes of acute gout and who had the following characteristics: 34 men, four women, age 40–80 years mean 54; inpatients 16, domiciliary visits 9, Accident and Emergency 7, and clinic 10. Chronic diuretic use was implicated in eight and excessive alcohol in four of 10 excessive alcohol, three of eight women. Figure 1 shows the SUA values for acute and interval gout.

Crystal verified cases

<table>
<thead>
<tr>
<th>Urate (mmol/l)</th>
<th>Acute</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Urate estimations after the episode were made either before commencement of allopurinol or within three months. Values before the episode (within six months) were available from the files of 20 patients. The upper limit of the normal range of SUA in our laboratory is 0.45 mmol/l in men and 0.38 in women. Figure 1 shows the SUA values for the acute and intercritical phases. The respective median values were 0.44 and 0.56 mmol/l for the whole group and 0.42 and 0.54 mmol/l for crystal verified cases (p = 0.004, Mann-Whitney). During the acute episode a normal SUA value was found in 43% as follows: 16 men and two women; 11 of 22 monoarticular, five of 12 polyarticular, and two of four chronic tophaceous gout; four of 10 excessive alcohol, three of eight women. Figure 1 shows the SUA values for acute and interval gout.

SUA values for acute and intercritical phases. The respective median values were 0.44 and 0.56 mmol/l for the whole group and 0.42 and 0.54 mmol/l for crystal verified cases (p = 0.004, Mann-Whitney). During the acute episode a normal SUA value was found in 43% as follows: 16 men and two women; 11 of 22 monoarticular, five of 12 polyarticular, and two of four chronic tophaceous gout; four of 10 excessive alcohol, three of eight women. Figure 1 shows the SUA values for acute and interval gout.

Routine laboratory investigation showed only a moderate increase of the acute phase reactants (erythrocyte sedimentation rate 20 mm 1st h, C reactive protein 2.9 mg/dl, fibrinogen 600 mg/dl).

Antineutrophil cytoplasmatic antibodies (ANCA), antinuclear antibodies, immune complexes, and cryoglobulins were absent. Hepatitis B virus markers (antibodies to hepatitis B, anti-HBc, and anti-HBe) and the serum, nor were the antibodies anti-HIV1 and -HIV2.

On the contrary, anti-HCV antibodies were found using a third generation ELISA test (Abbott HCV EIA 3.0, Abbott Diagnostics, Wiesbaden-Dielenkheim, Germany). A qualitative ‘dot’ assay (Abbott HCV MA-TRIX, Abbott Diagnostics, Wiesbaden-Dielenkheim, Germany) showed that these antibodies were directed to the HC-34 core protein (anti-HBc, anti-HBe, and the HBs and HBc antigens) were not detected in the serum. From the time of the histopathological assessment of chronic hepatitis to that of the appearance of the cutaneous nodules the patient was not receiving any medical treatment.

The presence of viral RNA (indicative of active HCV replication) in the serum was demonstrated by a polymerase chain reaction.

J A LOGAN
E MORRISON
P E MCGILL

Department of Medicine and Rheumatology,
Stobhill NHS Trust, Glasgow, Scotland
Figure 1. (A) Medium sized artery with acute and chronic transmural inflammation without signs of extension of the process to the surrounding tissue. The lumen is partially obstructed by a thrombus (magnification × 40, haematoxylin and eosin stain). (B) A typical Langhans-type giant cell can be clearly seen in the upper left corner. Other giant cells are barely discernible along the lower edge. The infiltrate is mainly constituted of granulocytes and mononuclear cells. Eosinophils are present in very limited amounts (no more than 2% of the infiltrating cells) (magnification × 200, haematoxylin and eosin stain).

(PCR Primer 5’ UTR, Roche Diagnostic Systems, Branchburg, NJ, USA). The viral genotype was 2a (Inno-LIPA HCV, Nuclear Laser Medicine, Milan, Italy). Liver biopsy showed a mild, chronic hepatitis that was classified as grade 2, stage 2 according to a recently proposed scoring system. A skin biopsy specimen taken from a nodular lesion on the right leg showed inflammation and thrombosis of a medium sized dermal artery with presence of a number of Langhans type multinucleated giant cells (fig 1). An immunohistochemical procedure, using an anti-CD68/F4R1 monoclonal antibody (Dako, Glostrup, Denmark) showed a specific staining of the multinucleated giant cells, confirming the presence of other monocytic/ macrophagic elements in origin. On the other hand, this feature could be considered suggestive of a giant cells arteritis. An angiogram of the coeliac axis and the superior mesenteric artery did not show any aneurysmal dilatations in the small and medium sized arteries suggestive of polyarteritis nodosa. A clinical examination was completed that excluded any other infectious, immunomediated or neoplastic disorders, which could potentially be linked to the presence of granulomatous lesions of the medium sized arteries.

Corticosteroid therapy (6-methylprednisolone 16 mg per day) was started and was progressively tapered to a low dose maintenance regimen of 4 mg. The cutaneous lesions completely disappeared within four weeks after beginning this treatment.

In the patient described here GCA developed in limited areas in the skin of the right leg during the course of a chronic HCV infection. The persistence of HCV infection was demonstrated by the presence of anti-HCV antibodies, and of viral RNA in the serum whose genotype was compatible with the mild form of chronic hepatitis that had been reported by the liver histopathology. The diagnosis of GCA was confirmed by histopathological and immunohistochemical studies, which showed an inflammatory infiltrate in the walls of the medium sized arteries composed of numerous mononuclear cells and scattered Langhans-type giant cells. To our knowledge, this association has never been reported before in the medical literature.

Multi-nucleated giant cells are a common feature of the granulomas that may develop during various inflammatory reactions. These elements originate from the fusion of monocytes or macrophages, with the cooperation of adhesion molecules. Giant cell granulomas are the characteristic feature of the granulomatous vasculitides, including Wegener's granulomatosis.11 However, giant cell granulomas are the histopathological hallmark of two clinical entities, Takayasu's arteritis and Horton's arteritis. In the first the aorta and its branches (including the proximal coronary and renal arteries) are generally involved; in the second the temporal artery is classically affected and, more rarely, the extraoculal or intracranial branches of the carotid.12

The typically sudden onset of GCA, accompanied by fever and other generalised complaints, has raised the possibility that the disorder may be triggered by an infection although a convincing experimental support is lacking. However, a retrospective epidemiological study has shown that Horton's arteritis exhibits a regular, cyclic pattern of incidence, thus indirectly supporting the hypothesis of an infectious cause.13

It is known that different vasculitides may occur in HCV infected patients. Leucocytoclastic small vessel vasculitis has been widely reported in patients with chronic HCV infection and circulating mixed cryoglobulins.14 At the same time, conflicting data exist on the possible association between HCV infection and cutaneous vasculitis.15

This case adds yet another to the list of the different vasculitides that may be associated with HCV infection, and in addition provides support for the interesting, but as yet unproved hypothesis that granulomatous vasculitides of the medium sized vessels, including giant cell arteritis, may be an antigen driven process, possibly triggered by an infectious agent.16

CLAUDIO VITALI EDDI GALUZZO Rheumatology/Clinical Immunology Units of the University of Pisa, Italy
EUGENIO M CIANCIA Histopathology Unit of S Chiara Hospital of Pisa, Italy
ADOLFO MORETTI Blood Centre of S Chiara Hospital of Pisa, Italy
SANTINO MARCHI Gastroenterology Unit of the University of Pisa, Pisa, Italy

Correspondence to: Dr C Vitali, Rheumatology and Clinical Immunology Units, University of Pisa, via Roma 67, 56126 Pisa, Italy.


Long term follow up of von Willebrand factor and plasminogen activator inhibitor-1 in patients with polymyalgia rheumatica

In polymyalgia rheumatica (PMR) subclinical vasculitis is suggested in the pathogenesis of the disease.18 20 Von Willebrand factor (vWF), produced by endothelium and megakaryocytes, is an important haemostatic factor.19 In healthy people with ABO blood group O, vWF values are lower than there are people with a blood group other than O. Increased plasma concentrations of vWF indicate endothelial damage21 and are found in diseases that involve blood vessels including vasculitis.22 In PMR and giant cell arteritis, vWF concentrations persist after acute phase proteins are normalised,23 but a gradual decline over time is also reported.24 Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of tissue plasminogen activator and is released from endothelial cells.25 Decreased fibrinolysis because of increased vWF concentrations and high vWF concentrations persist after acute phase proteins are normalised,24 but a gradual decline over time is also reported.25 Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of tissue plasminogen activator and is released from endothelial cells.25 Decreased fibrinolysis because of increased plasma concentrations of vWF indicate endothelial damage and are found in diseases that involve blood vessels including vasculitis.22 In PMR and giant cell arteritis, vWF concentrations persist after acute phase proteins are normalised,23 but a gradual decline over time is also reported.24 Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of tissue plasminogen activator and is released from endothelial cells.25

We studied the plasma concentrations of vWF and of PAI-1 in PMR patients over time as the inflammation receded. The potentially confounding impact of ABO blood group and
of corticosteroid treatment on these values were also evaluated. Thirty seven patients (25 women, 12 men), mean (SD) age 70 (8) years, with PMR (criteria of Bird et al.) were prospectively followed up until 1996. Follow up blood samples were collected from 31 of the original 37 patients after a median time of 5.8 years (range 3.0–8.8). Five patients died during the observation period and no blood sample was available from one patient. For analysis of vWF and PAI-1, blood was collected in the morning. vWF and PAI-1 were measured as previously described. The plasma concentrations of vWF and PAI-1 increased significantly (p<0.05), while erythrocyte sedimentation rate (ESR), C reactive protein (CRP), fibrinogen and platelets decreased (p<0.0001) (table 1). From the patients with paired samples (n=31) two patients with clinical and laboratory relapse of PMR and three who had developed diabetic mellitus were excluded. In one patient information of the blood group was not available. Among the remaining patients, those with blood group non-O (n=16) showed high vWF values, median 197% which rose to 210% at follow up (p<0.05), but not in patients who had completed their treatment, median 112 IU/ml (6.4–17.0) to 11.8 IU/ml (8.6–13.8) at follow up.

In patients with non-O blood groups there was a correlation (Spearman rank test) between vWF and ESR, CRP, fibrinogen, and age at disease onset (r=0.63, r=0.63, r=0.79, p<0.01, p<0.05, p<0.01 respectively), but not in patients with blood group O. PAI-1 correlated with CRP (r=0.39, p<0.05) in all patients at diagnosis. There were no differences in ESR, CRP, fibrinogen, and platelet count between patients with and without blood group O. From these results we conclude that even in an inflammatory disease such as PMR, the ABO blood group and age influence the magnitude of the vWF concentrations and may explain the contradictions pertaining to vWF values reported in inflammatory diseases. In agreement with our earlier study PAI-1 values among PMR patients after several years of prednisolone treatment. Persistently high concentrations of vWF about six years after PMR diagnosis, suggest a continuous vascular dysfunction despite clinical and laboratory determined remission.

**Table 1** Laboratory data in 31 patients with PMR at diagnosis and at follow up after a median time of 5.8 years. Data are presented as medians and (interquartile range) and core analysed using Wilcoxon signed rank test

<table>
<thead>
<tr>
<th>Variables</th>
<th>At diagnosis</th>
<th>At follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESR (mm 1st h)</td>
<td>72 (49–84)</td>
<td>18** (13–29)</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>34 (13–76)</td>
<td>10** (23–28)</td>
</tr>
<tr>
<td>Fibrinogen (g/l)</td>
<td>5.6 (4.8–6.2)</td>
<td>2.8** (2.8–3.7)</td>
</tr>
<tr>
<td>Platelets (×10^12)</td>
<td>393 (314–482)</td>
<td>275** (235–319)</td>
</tr>
<tr>
<td>vWF (%)</td>
<td>175 (137–223)</td>
<td>199** (162–246)</td>
</tr>
<tr>
<td>PAI-1 activity (IU/l)</td>
<td>10.8 (6.7–16.3)</td>
<td>11.6* (9.3–14.3)</td>
</tr>
</tbody>
</table>

* p < 0.05, ** p < 0.0001. vWF = von Willebrand factor, PAI-1 = plasminogen activator inhibitor.

At diagnosis At follow up

![Figure 1 Plasma concentrations of vWF in 25 patients with PMR at diagnosis and at follow up subgrouped according to ABO blood group O (open boxes) and non-O (filled boxes). Data are presented with 16th, 25th, 50th, 75th, and 88th percentiles. Wilcoxon signed rank test was used for paired data and Mann-Whitney U test for unpaired data.](image)

**Septic arthritis by Mycoplasma hominis: a case report and review of the medical literature**

Septic arthritis caused by *M. hominis* is rarely diagnosed. We present a case of *M. hominis* septic arthritis in a renal transplant recipient. A 36 years old white man receiving haemodialysis was admitted to hospital for renal transplantation. Two weeks later, while taking cyclosporin A, azathioprine, prednisolone, vancomycin, aminoglycosides, he developed inflammation of the right knee. Serological examinations for cytomegalovirus (Ig G and M), hepatitis B and C, HIV, and Epstein-Barr virus were negative. A Mantoux test was positive. On physical examination he was not febrile and had arthritis of the right knee. Laboratory findings included a whole blood cell count of 9570/mm³, packed cell volume 22%, platelet count 224 000/mm³, creatinine 5 mg/dl, and uric acid 9 mg/dl. A chest radiograph was normal. A right knee roentgenogram showed soft tissue swelling without erosions or bone lesions. Arthrocentesis yielded 60 cc of cloudy yellow synovial fluid containing white blood cell count of 40 500/mm³ (80% polymorphonuclear neutrophils), glucose 114 mg/dl, and lactate dehydrogenase 341 IU/l. No crystals were seen. A direct Gram stain of the aspirate showed no microorganisms. There was no bacterial, fungal, and mycobacterial growth on cultures. Arthritis recurred and two further arthrocenteses were performed. The last aspiration revealed 120 cc of cloudy yellow low synovial fluid with white blood cell count 68 000/mm³ (82% polymorphonuclear neutrophils), glucose 30 mg/dl, and lactate dehydrogenase 728 IU/l. Deep venous thrombosis in the right leg was diagnosed and anticoagulant treatment was started. Twenty four hours later he developed a spontaneous haemarthrosis in the knee. Because there was no improvement of the haemarthrosis and the suspicion of septic arthritis by *M. tuberculosis* was high, open synovial biopsy with synovectomy was performed. Histological examination showed synovial hyperplasia and infiltration with polymorphonuclear cells. No granulomatous reaction nor mycobacteria were seen. Direct Gram and Ziehl-Nielsen stains

were negative. Normal aerobic and anaerobic cultures were also negative. Urethra, phar-ynx, and rectal cultures were negative. Serological tests for Salmonella, Brucella, Lyme, Q fever, Rubella, cytomegalovirus, and Epstein-Barr virus were negative. C reactive protein, rheumatoid factor, antinuclear anti-body, complement, and immunoglobulin val-uues were normal. After 48 hours incubation, the microbiology laboratory reported a growth in blood culture bottles (Bactec Plus, BACTEC 9240, BBL) from the second and third synovial fluid culture. The isola
grew as minute colonies on anaerobic agar me-
dium and was Gram stain negative. On 17 agar (bioMérieux), it showed a typical ‘fried egg’ appearance and hydrolysed arginine and was identified as *M. hominis*. Treatment with doxycycline 100 mg orally twice daily was
sufficient to chronic mycoplasmal infections,
serum immunoglobulin concentra-
tions were normal. We only performed one
measurement and we do not exclude tran-
sient hypogammaglobulinaemia. Optimal
treatment for *M. hominis* joints infections is
unknown. Doxycycline apparently only sup-
presses and does not eradicate the infection.
However, our patient had a good clinical
response without recurrent arthritis. If bac-
terial antigens in the joint are critical in the
resolution of the arthriti-
s. 

We illustrate the importance of considering infection with unusual organisms in immuno-
compromised hosts. Correct diagnosis will
be made only if mycoplasma infection is con-
sidered, and appropriate investigations
performed.

### Table 1 Summary data from reported cases of immunocompromised patients with *M. hominis* septic arthritis

<table>
<thead>
<tr>
<th>Reference</th>
<th>Age/sex</th>
<th>Site of infection</th>
<th>Predisposing factor(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>32/M</td>
<td>Knee and shoulder</td>
<td>Immunosuppressive drugs</td>
</tr>
<tr>
<td>1</td>
<td>25/F</td>
<td>Hip and knees</td>
<td>Immunosuppressive drugs</td>
</tr>
<tr>
<td>1</td>
<td>54/F</td>
<td>Hip and wrist</td>
<td>Immunosuppressive drugs</td>
</tr>
<tr>
<td>1</td>
<td>66/F</td>
<td>Knee and wrist</td>
<td>Immunosuppressive drugs</td>
</tr>
<tr>
<td>1</td>
<td>39/F</td>
<td>Shoulders, knees, thoracic and lumbar spine, toes, blood</td>
<td>Immunosuppressive drugs</td>
</tr>
<tr>
<td>1</td>
<td>63/M</td>
<td>Knee</td>
<td>Immunosuppressive drugs</td>
</tr>
<tr>
<td>1</td>
<td>NS</td>
<td>Knee</td>
<td>Hypogammaglobulinaemia</td>
</tr>
<tr>
<td>6</td>
<td>42/F</td>
<td>Knee</td>
<td>Hypogammaglobulinaemia</td>
</tr>
<tr>
<td>This paper</td>
<td>36/M</td>
<td>Knee</td>
<td>Immunosuppressive drugs</td>
</tr>
</tbody>
</table>

NS = not stated.
Serum uric acid in acute gout

J A LOGAN, E MORRISON and P E McGILL

Ann Rheum Dis 1997 56: 696-697
doi: 10.1136/ard.56.11.696a

Updated information and services can be found at:
http://ard.bmj.com/content/56/11/696.2

These include:

References
This article cites 4 articles, 0 of which you can access for free at:
http://ard.bmj.com/content/56/11/696.2#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/